AVTX

ANALYST NOTE: AVTX (Avalo Therapeutics, Inc.) Date: 2026-06-13 Current Price: $14.70

1. Structural Readiness

• State: Context-Only (No technical structure defined in source data)
• Conservative Entry: —
• Breakout Level: —
• Extension: —
• ATR Current: 7.8% (Very High)

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Immunology & Inflammation.
• Directness: High.
• Thesis Weighting: The company is a direct beneficiary of the Immunology & Inflammation theme through its lead asset, abdakibart. The thesis is strengthened by the specific focus on Hidradenitis Suppurativa (HS), a prevalent condition with significant unmet needs. While the company also holds assets in rare genetic conditions (PGM1-CDG and LADII), the immediate conviction driver is the immunology pipeline. The "Biotech & GLP-1" classification in the source data appears to be a thematic bucket for the broader immunology sector; the direct exposure is to the IL-1β pathway within the inflammatory disease space.

3. Business Overview

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immune-mediated inflammatory diseases and rare genetic conditions.

• Lead Asset (Abdakibart/AVTX-009): An anti-IL-1β monoclonal antibody. As of May 5, 2026, the Phase 2 LOTUS trial in adults with moderate to severe Hidradenitis Suppurativa (HS) successfully met its primary endpoint at both doses studied (150mg and 300mg).
• *Data:* The trial demonstrated a 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16 for the 150mg and 300mg doses, respectively, compared to a 25.6% placebo rate (p=0.018, p=0.015, and p=0.004 combined).
• *Next Step:* Management expects to advance abdakibart into a registrational Phase 3 program immediately following these results.
• Pipeline Diversification: The company maintains a late-stage pipeline for rare genetic conditions, including AVTX-801 (PGM1-CDG) and AVTX-803 (LADII), both in Phase III trials.
• Partnership & Milestones: The company has a collaboration with Eli Lilly. Management expects to pay Lilly up to $70 million in development and regulatory milestones. Upon commercialization, sales-based milestones could aggregate up to $650 million to Lilly and $70 million to Leap.
• Financial Runway: As of the March 23, 2026 filing, management stated that existing cash and proceeds from a recent offering are sufficient to fund operations for at least twelve months from the filing date, extending into 2029.

4. Archetype and Conviction

• Archetype: Growth Leader / Catalyst-Driven Biotech.
• Valuation Context: The financial spine indicates negative earnings for FY1 (-3.16) and FY2 (-3.15), consistent with a pre-revenue clinical-stage company. The valuation is driven entirely by the probability of success (PoS) of the Phase 3 program and the potential for future commercialization milestones.
• Conviction Stack:
• *Thesis Strength:* High. The Phase 2 data is statistically significant (p=0.004 combined) and shows a robust absolute improvement over placebo.
• *Evidence Quality:* Strong. The evidence is derived from primary SEC filings (10-Q/8-K) dated May 13, 2026, confirming the topline results.
• *Structural Quality:* Unknown. The lack of technical structure data prevents a full assessment of the setup quality.
• *Rerating Potential:* High. The transition from Phase 2 success to Phase 3 initiation is a critical inflection point for biotech valuations, provided the cash runway (into 2029) supports the increased R&D spend management expects.
• ATR Context: The current ATR of 7.8% (Very High) suggests the market is pricing in significant uncertainty or excitement regarding the Phase 3 initiation. This volatility requires careful position sizing if a technical entry were to be established later.

5. Invalidation, Strengthening, and Gaps

• What Would Strengthen:
• Confirmation of the Phase 3 trial design and start date.
• Positive interim data from the Phase 3 trials for AVTX-801 or AVTX-803.
• Announcement of a new partnership or licensing deal for abdakibart.
• What Would Invalidate:
• Regulatory feedback from the FDA indicating the Phase 2 endpoints are insufficient for Phase 3 design.
• Unexpected safety signals emerging in the Phase 3 planning phase.
• A cash burn rate significantly higher than projected, threatening the "into 2029" runway.
• Gaps in Evidence:
• Cash Position Details: While the runway is stated as "into 2029," the exact cash balance and monthly burn rate as of June 13, 2026, are not detailed in the provided snippets.
• Phase 3 Specifics: The specific design, patient count, and timeline for the upcoming Phase 3 program are not yet detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Phase 2 LOTUS trial met primary endpoint with p=0.004 combined significance; Management confirms advancement to Phase 3; Cash runway extends into 2029. Key risks: No technical structure defined for entry/exit; Very high ATR (7.8%) indicates elevated volatility; R&D expenses expected to increase significantly; Binary nature of Phase 3 initiation. Sizing hint: Position size should be reduced relative to the ATR to account for the "Very High" volatility and lack of defined structural support. Expected path: Management expects to advance abdakibart into Phase 3, leading to increased R&D spend and potential dilution or capital raises if cash flow is insufficient, while the stock price reacts to the confirmation of the Phase 3 protocol. Expected horizon: 12 to 24 months for Phase 3 initiation and design finalization. Failure mode to watch: FDA feedback rejecting the Phase 2 data as a basis for registration or a cash shortfall requiring immediate dilutive financing before 2029.